Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Compliance of sildenafil treatment for erectile dysfunction and factors affecting it

Abstract

To assess the compliance of treatment, its affecting factors, and reasons for dropout, a questionnaire was mailed to a cohort of 2139 subjects who received sildenafil prescriptions for erectile dysfunction (ED) at our institution from 1999 to 2002. A total of 726 subjects (34%) with a mean age of 67 years answered the questionnaires. The response rate for sildenafil treatment was 67%. Of these sildenafil responders, 43% reported that they continued using sildenafil while 57% did not, in a mean follow-up of 3 years. Common reasons for discontinuation were effect below expectations, high cost, loss of interest in sex, and inconvenience in obtaining sildenafil. The continuers showed a higher rate than the discontinuers (P<0.05) of having tried other treatments, dose titration, and a dose higher than 50 mg. The discontinuers reported having a lower mean responding dose and improvement score post sildenafil treatment than the continuers. In conclusion, effect below expectations was the leading reason for discontinuation of sildenafil treatment. How ED subjects tried the medication and the adequacy of education in the initial treatment period may impact the compliance of sildenafil treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Wysowski DK, Swann J . Use of medications for erectile dysfunction in the United States, 1996 through 2001. J Urol 2003; 169: 1040–1042.

    Article  Google Scholar 

  2. Jiann BP, Yu CC, Su CC . Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sale. Int J Impot Res 2004; 16: 527–530.

    Article  CAS  Google Scholar 

  3. Jiann BP, Yu CC, Tsai JY, Wu TT, Lee YH, Huang JK . What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res 2003; 15: 412–417.

    Article  Google Scholar 

  4. Hackett GI, Milledge A . A 12-month follow up of 260 patients taking sildenafil. NHS clinical experience. In: Fourth Congress of the European Society for Sexual and Impotence Research (ESSIR) 2001, 30 September–3 October 2001 (poster 171).

  5. Casabe A, Cobreros C, Bechara A, Roletto L, Cheliz G, Hochman S et al. Drop out reason in responders to sildenafil. Int J Impot Res 2001; 13(Suppl 2): S5, (moderated poster 9).

    Google Scholar 

  6. Klotz T, Mathers M, Klotz R, Sommer F . Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? Int J Impot Res 2005; 17: 2–4.

    Article  CAS  Google Scholar 

  7. Son H, Park H, Kim SW, Paick JS . Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004; 6: 117–120.

    CAS  PubMed  Google Scholar 

  8. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC . Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541–1547.

    Article  CAS  Google Scholar 

  9. Seftel AD . Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003; 169: 1999–2007.

    Article  CAS  Google Scholar 

  10. Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med 2000; 160: 3401–3405.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B-P Jiann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jiann, BP., Yu, CC., Su, CC. et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 18, 146–149 (2006). https://doi.org/10.1038/sj.ijir.3901379

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901379

Keywords

  • compliance
  • discontinuation
  • sildenafil
  • erectile dysfunction
  • phosphodiesterase type 5 inhibitors

This article is cited by

Search

Quick links